Category: Triple-Neg Breast Cancer

LitAlert ~~ GeneLit.com

    • Dextran-modified Quercetin-Cu(II)/hyaluronic acid nanomedicine with natural poly(ADP-ribose) polymerase inhibitor and dual targeting for programmed synthetic lethal therapy in triple-negative breast cancer.
    • Cheng HW, Chiang CS, Ho HY, Chou SH, Lai YH, Shyu WC, Chen SY.
    • J Control Release. 2020 Dec 2:S0168-3659(20)30718-5. doi: 10.1016/j.jconrel.2020.11.061. Epub ahead of print.

    • Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer.
    • Chávarri-Guerra Y, Marcum CA, Hendricks CB, Wilbur D, Cescon T, Hake C, Abugattas J, Rodriguez Y, Villarreal-Garza C, Yang K, Cervantes A, Sand S, Castillo D, Herzog J, Mokhnatkin J, Sedrak MS, Soto-Perez-de-Celis E, Weitzel JN.
    • J Geriatr Oncol. 2020 Dec 1:S1879-4068(20)30500-2. doi: 10.1016/j.jgo.2020.11.008. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
    • Han Y, Yu X, Li S, Tian Y, Liu C.
    • Front Oncol. 2020 Nov 25;10:578095. doi: 10.3389/fonc.2020.578095.

    • Insights into the impacts of BRCA mutations on clinicopathology and management of early-onset triple-negative breast cancer.
    • Ye F, He M, Huang L, Lang G, Hu X, Shao Z, Di G, Cao A.
    • Front Oncol. 2020 Nov 24;10:574813. doi: 10.3389/fonc.2020.574813.

    • LitAlert ~~ GeneLit.com

    • A Review of Natural Therapies Potentially Relevant in Triple Negative Breast Cancer Aimed at Targeting Cancer Cell Vulnerabilities.
    • Webb MJ, Kukard C.
    • Integr Cancer Ther. 2020 Jan-Dec;19:1534735420975861. doi: 10.1177/1534735420975861. [First Published November 27, 2020.]

    • Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    • Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE.
    • Ann Oncol. 2020 Nov 23:S0923-7534(20)43164-3. doi: 10.1016/j.annonc.2020.11.009. Epub ahead of print.

    • Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in Triple Negative Breast Cancer: the TNT trial.
    • Sipos O, Tovey H, Quist J, Haider S, Nowinski S, Gazinska P, Kernaghan S, Toms C, Maguire S, Orr N, Linn SC, Owen J, Gillett C, Pinder SE, Bliss JM, Tutt A, Cheang MCU, Grigoriadis A.
    • Ann Oncol. 2020 Oct 21:S0923-7534(20)42977-1. doi: 10.1016/j.annonc.2020.10.475. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative.
    • Vidula N, Ellisen LW, Bardia A.
    • J Natl Compr Canc Netw. 2020 Oct 15:1-9. doi: 10.6004/jnccn.2020.7600. Epub ahead of print.

    • The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
    • De Palma FDE, Monaco VD, Pol JG, Kremer M, D'Argenio V, Stoll G, Montanaro D, Uszczynska-Ratajczak B, Klein CC, Vlasova A, Botti G, D'Aiuto M, Baldi A, Guigó R, Kroemer G, Maiuri MC, Salvatore F.
    • Pharmacol Res. 2020 Oct 14:105249. doi: 10.1016/j.phrs.2020.105249. Epub ahead of print.

    • The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.
    • Okano M, Nomizu T, Tachibana K, Nagatsuka M, Matsuzaki M, Katagata N, Ohtake T, Yokoyama S, Arai M, Nakamura S.
    • J Hum Genet. 2020 Oct 12. doi: 10.1038/s10038-020-00849-y. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
    • Huynh MM, Pambid MR, Jayanthan A, Dorr A, Los G, Dunn SE.
    • Expert Opin Investig Drugs. 2020 Sep 1. doi: 10.1080/13543784.2020.1818067. Epub ahead of print.
    • Review

    • Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    • Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Ferguson NL, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen MB, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom PJ, Alexander B, Brown C, Pusztai L, Ross JS, Ramkissoon SH.
    • Oncologist. 2020 Sep 1. doi: 10.1634/theoncologist.2020-0449. Epub ahead of print.